thc biomed intl ltd - THCBF

THCBF

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 10.00K

Last Updated:

Jan 14, 2026, 11:40 AM EDT

Company Overview: thc biomed intl ltd - THCBF

THCBF Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

Market Cap

$0.00

Shares Outstanding

163.94M

Public Float

N/A

Beta

-191.74

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.02

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.42K

 

THCBF Performance

No Data Available

THCBF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About thc biomed intl ltd - THCBF

THC BioMed International Ltd. engages in the research, development and cultivation of medical cannabis. It offers horticulture training, record keeping and documenting, research studies and analytical services. The company was founded in 2012 and is headquartered in Kelowna, Canada.

THCBF At a Glance

THC BioMed International Ltd.
20033 Towne Centre
Kelowna, British Columbia V1Y 9H2
Phone 1-844-842-6337 Revenue 2.63M
Industry Agricultural Commodities/Milling Net Income -2,415,663.40
Sector Process Industries Employees N/A
Fiscal Year-end 07 / 2023
View SEC Filings

THCBF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.064
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

THCBF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 6.38
Total Asset Turnover 0.207

THCBF Liquidity

Current Ratio 0.627
Quick Ratio 0.219
Cash Ratio 0.071

THCBF Profitability

Gross Margin -27.539
Operating Margin -64.796
Pretax Margin -91.792
Net Margin -91.792
Return on Assets -18.988
Return on Equity -36.469
Return on Total Capital -27.104
Return on Invested Capital -31.534

THCBF Capital Structure

Total Debt to Total Equity 64.721
Total Debt to Total Capital 39.291
Total Debt to Total Assets 30.429
Long-Term Debt to Equity 13.97
Long-Term Debt to Total Capital 8.481
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Thc Biomed Intl Ltd - THCBF

Collapse All in section
All values USD millions. 2019 2020 2021 2022 5-year trend
Sales/Revenue
1.13M 3.10M 2.96M 2.63M
Sales Growth
+54.96% +175.77% -4.63% -11.11%
Cost of Goods Sold (COGS) incl D&A
1.59M 3.04M 3.93M 3.36M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
456.97K 753.65K 768.68K 731.62K
Depreciation
456.97K 753.65K 768.68K 731.62K
Amortization of Intangibles
- - - -
-
COGS Growth
+78.32% +90.76% +29.23% -14.50%
Gross Income
(466.68K) 66.67K (965.06K) (724.72K)
Gross Income Growth
-180.26% +114.29% -1,547.54% +24.90%
Gross Profit Margin
-41.46% +2.15% -32.60% -27.54%
2019 2020 2021 2022 5-year trend
SG&A Expense
7.60M 1.48M 1.37M 963.54K
Research & Development
- - - -
-
Other SG&A
7.60M 1.48M 1.37M 963.54K
SGA Growth
+264.10% -80.55% -7.46% -29.56%
Other Operating Expense
31.09K 26.56K 29.13K 16.95K
Unusual Expense
1.41M (1.59M) 2.29M 681.22K
EBIT after Unusual Expense
(9.51M) 151.76K (4.66M) (2.39M)
Non Operating Income/Expense
(10.36K) (3.68K) (1.73K) 365.64K
Non-Operating Interest Income
536.5476199507999 43.0931447751 101.1873637998 4.70K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
80.21K 268.13K 330.82K 394.88K
Interest Expense Growth
-35.63% +234.30% +23.38% +19.36%
Gross Interest Expense
80.21K 268.13K 330.82K 394.88K
Interest Capitalized
- - - -
-
Pretax Income
(9.60M) (120.06K) (4.99M) (2.42M)
Pretax Income Growth
+1.88% +98.75% -4,054.78% +51.57%
Pretax Margin
-852.53% -3.87% -168.49% -91.79%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(9.60M) (120.06K) (4.99M) (2.42M)
Minority Interest Expense
- - - -
-
Net Income
(9.60M) (120.06K) (4.99M) (2.42M)
Net Income Growth
+1.88% +98.75% -4,054.78% +51.57%
Net Margin Growth
-852.53% -3.87% -168.49% -91.79%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(9.60M) (120.06K) (4.99M) (2.42M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(9.60M) (120.06K) (4.99M) (2.42M)
EPS (Basic)
-0.0724 -0.0008 -0.0305 -0.0147
EPS (Basic) Growth
+16.88% +98.90% -3,712.50% +51.80%
Basic Shares Outstanding
- - - 132.62M
-
EPS (Diluted)
-0.0724 -0.0008 -0.0305 -0.0147
EPS (Diluted) Growth
+16.88% +98.90% -3,712.50% +51.80%
Diluted Shares Outstanding
- - - 132.62M
-
EBITDA
(7.64M) (684.49K) (1.59M) (973.59K)
EBITDA Growth
-261.46% +91.04% -132.79% +38.90%
EBITDA Margin
-678.85% -22.05% -53.82% -37.00%

Thc Biomed Intl Ltd in the News